Press Releases Lipidor AB

Equities

Delayed Nasdaq Stockholm Other stock markets 12:30:00 14/05/2024 pm IST			5-day change	1st Jan Change
0.22 ^SEK	0.00%		-5.17%	-56.35%

22/04	Lipidor AB Postpones the Publication of Annual Report for 2023	CI
21/03	Lipidor AB Announces Approval for Start of Phase III Clinical Trial of Psoriasis Candidate AKP02G2	CI

NOTICE OF ANNUAL GENERAL MEETING IN LIPIDOR AB (PUBL)	07/05	AQ
Lipidor AB announces new date for publication of Annual Report 2023	22/04	AQ
NOTICE OF EXTRAORDINARY GENERAL MEETING IN LIPIDOR AB (PUBL)	10/04	AQ
Lipidor resolves on a rights issue of approximately SEK 58.0 million and enters into a co-investment agreement which secures funding for the implementation of the upcoming phase III study	10/04	AQ
Lipidor completes planned divestment of shares in Emollivet	26/03	AQ
Lipidor announces approval for start of Phase III clinical trial of psoriasis candidate AKP02G2	21/03	AQ
Lipidor adds capital through sale of shares	06/03	AQ
Lipidor AB (publ) publishes year-end report for 2023	28/02	AQ
Lipidor completes SEK 1.7 million sale of animal segment patent	24/01	AQ
Lipidor adds 1.1 MSEK through sale of shares in associated company and agreement of loan	21/12	AQ
Lipidor applies to the Indian Medical Products Agency to start a Phase III study of AKP02G2	20/12	AQ
Lipidor presents Nomination Committee	05/12	AQ
Lipidor changes Certified Adviser to Carnegie Investment Bank AB (publ)	30/11	AQ
Lipidor AB (publ) publishes interim report for Q3 2023	22/11	AQ
Lipidor submits new patent application	27/23/27	AQ
Lipidor extends and expands cooperation with RELIFE	18/23/18	AQ
Lipidor signs agreement for clinical phase III study	20/23/20	AQ
Correction: Lipidor AB (publ) publishes interim report for Q2 2023	24/23/24	AQ
Lipidor AB (publ) publishes interim report for Q2 2023	23/23/23	AQ
Lipidor – Announcement of short-term funding	29/23/29	AQ

No results for this search